Elicio Therapeutics, Inc.
ELTX
$4.80
$0.040.84%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 25.66% | -160.59% | 38.88% | -32.16% | 16.05% |
Total Depreciation and Amortization | 5.17% | -1.02% | 1.03% | 1.40% | 4.76% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -86.65% | 391.24% | -250.02% | 448.36% | -8.94% |
Change in Net Operating Assets | 109.14% | 38.30% | 146.13% | -69.55% | -134.18% |
Cash from Operations | -20.21% | 18.53% | 26.35% | -22.51% | -90.84% |
Capital Expenditure | -- | 100.00% | -- | -- | 100.00% |
Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | 100.00% | -1,500.00% | -- | 100.00% |
Total Debt Issued | -100.00% | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -98.04% | 3,563.29% | -97.13% | 57.51% | 11,565.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 100.00% | -- | -- | -- | -- |
Cash from Financing | -99.26% | 9,632.28% | -97.13% | 57.46% | 11,568.33% |
Foreign Exchange rate Adjustments | -25.00% | 187.80% | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -136.29% | 370.45% | -694.06% | 62.16% | 44.00% |